文献速递消化道肿瘤放疗

剂量递增与标准化疗放疗对局部晚期直肠癌的九年随机II期试验结果

Dose-Escalated Versus Standard Neoadjuvant Chemoradiation Therapy for Locally Advanced Rectal Cancer: Nine-Year Results of a Randomized Phase 2 Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-07-15

该前瞻性随机II期试验纳入106例II/III期直肠腺癌患者,比较术前同步整合推量化放疗(SIB-CRT)与标准化放疗(CRT)的安全性和疗效。中位随访116.6个月后,SIB-CRT组在无病生存、总生存、无转移生存、局部控制和癌症特异性生存方面均优于CRT组,而病理完全缓解率无显著差异。

核心结论

  • 新辅助化放疗期间通过同步整合推量进行剂量递增可带来更优的长期生存结局。
  • SIB-CRT对局部疾病和微转移的强化控制可能 contributes 于这些稳健结果。
  • 剂量递增可作为优化局部晚期直肠癌长期治愈的策略,尤其对不适合化疗的患者。

研究设计与样本

  • 前瞻性、随机II期试验(NCT02195141),纳入II/III期直肠腺癌患者。
  • 患者按1:1随机分配至CRT(盆腔50 Gy/25次)或SIB-CRT(盆腔50 Gy/25次,同时PGTV推量至56 Gy,如有侧方转移淋巴结推量至60 Gy)。
  • 计划在CRT后6-8周进行根治性手术。
  • 主要终点为病理完全缓解率;次要终点包括无病生存、总生存、无转移生存、局部控制、癌症特异性生存和毒性。
  • 2013年8月至2015年2月共入组106例患者:SIB-CRT组55例,CRT组51例。

主要发现

  • 急性3级毒性发生率:SIB-CRT组14.5%,CRT组19.6%,主要表现为放射性皮炎。

临床怎么用

  • 对于局部晚期直肠癌,尤其是化疗不合格患者,可考虑新辅助SIB-CRT剂量递增策略。
  • SIB-CRT未显著增加急性3级毒性,安全性可接受。
  • 尽管病理完全缓解率相当,SIB-CRT可能通过强化局部和微转移控制改善长期生存。

局限性

  • II期试验,样本量有限(106例),需III期试验验证。
  • 探索性亚组分析结果需谨慎解读。
  • 未报告长期毒性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the safety and efficacy of preoperative simultaneous integrated boost chemoradiation therapy (SIB-CRT) versus standard chemoradiation therapy (CRT) for locally advanced rectal cancer. METHODS AND MATERIALS: This prospective, randomized phase II trial (NCT02195141) enrolled patients with stage II/III rectal adenocarcinoma. Patients were randomly assigned (1:1) to CRT (50 Gy/25 fx to the pelvis) or SIB-CRT (50 Gy/25 fx to the pelvis with a simultaneous integrated boost of 56 Gy to PGTV and 60 Gy to lateral metastatic nodes if present). Radical surgery was planned 6-8 weeks after CRT. The primary endpoint was pathologic complete response (pCR) rate; secondary endpoints were disease-free survival (DFS), overall survival, metastasis-free survival, local control, cancer-specific survival, and toxicity. RESULTS: From August 2013 to February 2015, 106 patients were enrolled: 55 in the SIB-CRT group and 51 in the CRT group. Acute grade 3 toxicity occurred in 14.5% (SIB-CRT) and 19.6% (CRT) of patients, primarily manifested as radiation dermatitis. Curative treatment (radical surgery or watch-and-wait) was achieved in 89.1% (49/55) of SIB-CRT patients and 78.4% (40/51) of CRT patients (P = .135). After a median follow-up of 116.6 months, the SIB-CRT group showed superior 9-year outcomes in the intention-to-treat population: DFS (70.8% vs 47.4%; hazard ratio [HR], 0.46; P = .013), overall survival (74.3% vs 48.9%; HR, 0.43; P = .008), metastasis-free survival (70.8% vs 47.2%; HR, 0.48; P = .017), local control (87.1% vs 70.1%; HR, 0.40; P = .038) and cancer-specific survival (77.4% vs 57.2%, P = .027). Similar benefits were observed in the curative treatment cohort. The pCR rates were comparable (15.2% vs 18.4%, P = .695). Exploratory subgroup analysis showed that the survival benefit of SIB-CRT was statistically significant in patients who did not receive perioperative chemotherapy (9-year DFS, 70.8%; HR, 0.343; P = .014), whereas no additional benefit was observed in those receiving chemotherapy. CONCLUSIONS: Dose escalation through simultaneous integrated boost during neoadjuvant CRT translates into superior long-term survival outcomes. Despite comparable pCR rates, the intensified control of both local disease and micrometastases by SIB-CRT, coupled with its significant superiority within the chemotherapy-naive subgroup, likely contributed to these robust results. These findings establish dose escalation as a potent strategy for optimizing long-term cure in the modern management of locally advanced rectal cancer, particularly in chemotherapy-ineligible patients.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Li H, Wang N, Xu T, et al. Dose-Escalated Versus Standard Neoadjuvant Chemoradiation Therapy for Locally Advanced Rectal Cancer: Nine-Year Results of a Randomized Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 42456783. doi:10.1016/j.ijrobp.2026.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。